First Header Logo Second Header Logo

Connection

Karl-Erik Andersson to Cell Line, Tumor

This is a "connection" page, showing publications Karl-Erik Andersson has written about Cell Line, Tumor.
Connection Strength

0.416
  1. Björkelund H, Gedda L, Barta P, Malmqvist M, Andersson K. Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²5I-EGF. PLoS One. 2011; 6(9):e24739.
    View in: PubMed
    Score: 0.075
  2. Björkelund H, Gedda L, Andersson K. Comparing the epidermal growth factor interaction with four different cell lines: intriguing effects imply strong dependency of cellular context. PLoS One. 2011 Jan 31; 6(1):e16536.
    View in: PubMed
    Score: 0.071
  3. Björkelund H, Gedda L, Andersson K. Avoiding false negative results in specificity analysis of protein-protein interactions. J Mol Recognit. 2011 Jan-Feb; 24(1):81-9.
    View in: PubMed
    Score: 0.071
  4. Gedda L, Björkelund H, Andersson K. Real-time immunohistochemistry analysis of embedded tissue. Appl Radiat Isot. 2010 Dec; 68(12):2372-6.
    View in: PubMed
    Score: 0.068
  5. Björke H, Andersson K. Automated, high-resolution cellular retention and uptake studies in vitro. Appl Radiat Isot. 2006 Aug; 64(8):901-5.
    View in: PubMed
    Score: 0.051
  6. Altai M, Varasteh Z, Andersson K, Eek A, Boerman O, Orlova A. In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors. Cancer Biother Radiopharm. 2013 Apr; 28(3):187-95.
    View in: PubMed
    Score: 0.021
  7. Orlova A, Hofström C, Strand J, Varasteh Z, Sandstrom M, Andersson K, Tolmachev V, Gräslund T. [99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours. Eur J Nucl Med Mol Imaging. 2013 Feb; 40(3):439-49.
    View in: PubMed
    Score: 0.020
  8. Tolmachev V, Orlova A, Pehrson R, Galli J, Baastrup B, Andersson K, Sandström M, Rosik D, Carlsson J, Lundqvist H, Wennborg A, Nilsson FY. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res. 2007 Mar 15; 67(6):2773-82.
    View in: PubMed
    Score: 0.014
  9. Tolmachev V, Nilsson FY, Widström C, Andersson K, Rosik D, Gedda L, Wennborg A, Orlova A. 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med. 2006 May; 47(5):846-53.
    View in: PubMed
    Score: 0.013
  10. Persson M, Tolmachev V, Andersson K, Gedda L, Sandström M, Carlsson J. [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur J Nucl Med Mol Imaging. 2005 Dec; 32(12):1457-62.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.